Plain-English translation of NCT05635643 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called , which works by targeting a specific protein on immune cells to help your body fight cancer. Researchers want to find the safest and most effective dose of this medication, and they're also testing whether it works better when combined with another cancer drug called . The trial will include approximately 87 participants with advanced solid tumors.
Many people with advanced cancer have limited treatment options, especially after standard therapies stop working. This medication represents a new approach to boosting the immune system's ability to recognize and destroy cancer cells, offering hope for patients who need new alternatives.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the medication through a vein, possibly at a clinic or hospital. Depending on which group you're in, you might receive alone or combined with another drug. You'll have regular visits for blood tests, imaging scans, and physical exams to monitor how you're responding to treatment and check for side effects. Some participants may also have tumor biopsies to help researchers understand how the medication is working.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States